Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALOFEC AdMSCs for Fecal Incontinence (Phase IIb)
2024-515766-13-00Phase 2Authorised
- Sponsor
- Fundación IMABIS
- Start
- Dec 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Alofec in fecal incontinence (FI) (3 arms), sponsored by Fundación IMABIS. Primary endpoints: Cumulative incidence of adverse events attributed to study therapy at 12 months, Change in Jorge-Wexner incontinence score and 3 more. Planned start Dec 2024; status: authorised.
02
Drugs
Alofec
03
Conditions
fecal incontinence (FI)
Beyond the preview
Go deeper on 2024-515766-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515766-13-00.